![Ken Warrington](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ken Warrington
Direktor/Vorstandsmitglied bei BIOSTEM TECHNOLOGIES INC
Vermögen: - $ am 31.05.2024
Aktive Positionen von Ken Warrington
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
BIOSTEM TECHNOLOGIES INC | Direktor/Vorstandsmitglied | 01.03.2022 | - |
Corporate Officer/Principal | 29.10.2019 | 01.03.2022 |
Karriereverlauf von Ken Warrington
Ehemalige bekannte Positionen von Ken Warrington
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
GENSCRIPT PROBIO USA INC. | Corporate Officer/Principal | 01.01.2020 | 01.12.2021 |
Biostem Life Sciences, Inc. | Geschäftsführer | 01.06.2019 | 01.05.2020 |
Lacerta Therapeutics, Inc.
![]() Lacerta Therapeutics, Inc. BiotechnologyHealth Technology Lacerta Therapeutics, Inc. operates as a a clinical stage gene therapy company. The firm engages in development, production, and application of AAV vectors. The company was founded by Nicholas Muzyczka, Barry Byrne, Arun Srivastava, Coy Heldermon, Sergei Zolothukin, Kenneth Warrington, Ronald Mandel, Toadd E. Golde and Edgardo Rodriguez in 2017 and is headquartered in Alachua, FL. | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2017 | 01.05.2019 |
Ausbildung von Ken Warrington
The St. Lawrence College | Undergraduate Degree |
University of Florida | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 6 |
Vereinigtes Königreich | 2 |
Operativ
Corporate Officer/Principal | 2 |
Director/Board Member | 1 |
Chief Operating Officer | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
BIOSTEM TECHNOLOGIES INC | Health Technology |
Private Unternehmen | 3 |
---|---|
Biostem Life Sciences, Inc. | |
GENSCRIPT PROBIO USA INC. | |
Lacerta Therapeutics, Inc.
![]() Lacerta Therapeutics, Inc. BiotechnologyHealth Technology Lacerta Therapeutics, Inc. operates as a a clinical stage gene therapy company. The firm engages in development, production, and application of AAV vectors. The company was founded by Nicholas Muzyczka, Barry Byrne, Arun Srivastava, Coy Heldermon, Sergei Zolothukin, Kenneth Warrington, Ronald Mandel, Toadd E. Golde and Edgardo Rodriguez in 2017 and is headquartered in Alachua, FL. | Health Technology |
- Börse
- Insiders
- Ken Warrington
- Erfahrung